NetworkNewsBreaks – Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) Secures $16M Grant from CIRM toward Phase 3 Clinical Trial of NurOwn® in ALS

Shares of Brainstorm Cell Therapeutics (NASDAQ: BCLI) are up more than 8% this morning after the company said it has been awarded a grant of $16 million by the California Institute for Regenerative Medicine (CIRM) to support the pivotal phase 3 study of NurOwn® for the treatment of amyotrophic lateral sclerosis (ALS). This grant signifies an endorsement from CIRM of the company’s approach to treat ALS using adult stem cells. The phase 3 clinical trial investigating NurOwn in ALS is expected to enroll approximately 200 patients and will be measured by the ALSFR-S score responder analysis. “This substantial award provides further support for our technology and clinical program, and recognizes the importance of developing effective treatments for patients afflicted with ALS,” Brainstorm president and CEO Chaim Lebovits stated in the news release.

To view the full press release, visit:

About Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double-blind, placebo-controlled clinical trial conducted in the U.S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo. For more information, visit the company’s website at

About NetworkNewsBreaks

NetworkNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s